FY19 ended on a high as sales and operating profit exceeded management’s pre-set targets – driven by royalties and the sales milestone of Darzalex. Given its robust traction, Darzalex should achieve the $4bn sales mark in FY20 (vs. FY19: $3bn). While operating profit could come under pressure as the company accelerates development of potential next winners, we are less concerned as the focused R&D approach bodes well for the mid/long term. An announcement of a partnership for
21 Feb 2020
Strong finish to FY19; partnership for Epcoritamab expected soon
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong finish to FY19; partnership for Epcoritamab expected soon
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
21 Feb 2020 -
Author:
Sumit Sayal -
Pages:
4
FY19 ended on a high as sales and operating profit exceeded management’s pre-set targets – driven by royalties and the sales milestone of Darzalex. Given its robust traction, Darzalex should achieve the $4bn sales mark in FY20 (vs. FY19: $3bn). While operating profit could come under pressure as the company accelerates development of potential next winners, we are less concerned as the focused R&D approach bodes well for the mid/long term. An announcement of a partnership for